For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing. The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, ...
By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback